- The company's distinctive dual strategy,
devised to help it penetrate developing and developed regions, has
fuelled its success
LONDON, Sept. 29, 2014
/PRNewswire/ -- Based on its recent analysis of the therapeutic
proteins market, Frost & Sullivan recognises ADOCIA with the
2014 European Frost & Sullivan Award for Technology Innovation
Leadership. By adopting a flexible business model that promotes
partnerships and collaboration with major players in the
pharmaceutical industry, ADOCIA has managed to maintain a steady
pace of innovation in the therapeutic proteins space.
"ADOCIA's core technology is BioChaperone®, which enhances the
effectiveness and safety of a broad spectrum of therapeutic
proteins that have already been approved," said Frost &
Sullivan Industry Analyst Cecilia Van
Cauwenberghe. "The company constantly strategizes to boost
the suitability and ease of use of BioChaperone® so as to make the
therapeutic proteins in the market accessible to the masses."
Essentially, BioChaperone® is a molecular delivery system of
therapeutic proteins designed to improve their performance. This
novel, heparin bio-inspired technology is based on cutting-edge
polymers that can chaperone therapeutic proteins. As such, one of
the most notable results of utilising the BioChaperone® molecular
delivery system of proteins is that the same properties as heparin
are conferred on to the complex, while avoiding the anticoagulant
activity specific of heparin. This can result in multiple
improvements, including the reduction of the frequency of
application and dose required (e.g. with a growth factor,
BioChaperone® PDGF-BB), the acceleration of the action of the
protein (e.g. with prandial insulins, BioChaperone® Lispro and
HinsBet®) or the ability to combine proteins known to be unmixable
(e.g. insulin glargine and insulin lispro in BioChaperone®
Combo).
Thus far, the proprietary BioChaperone® technological platform
has enabled the successful completion of two phase I and II studies
on the formulation of a fast-acting human insulin (HinsBet®). One
Phase I and two Phase IIa studies of an ultra-fast-acting insulin
(BioChaperone Lispro U100), along with a Phase I/II study on a
unique combination of insulin glargine, the gold-standard of basal
insulin and prandial insulin lispro (BioChaperone® Combo), have
also been completed.
At this stage, ADOCIA's BioChaperone® innovations are mainly
focused on insulin formulation (three out of the four products in
clinical development are insulins). ADOCIA's main product,
BioChaperone® Lispro U100, is an ultra-fast-acting formulation of
insulin analog lispro, which was created to improve post-prandial
glycaemic control and facilitate the development of innovative
device-drug combinations, such as the artificial pancreas.
To strengthen its presence in the therapeutic proteins market,
ADOCIA has also advanced towards the formulation of monoclonal
antibodies for cancer and inflammatory diseases. More recently,
ADOCIA diversified its portfolio to specifically address oncology.
Its focus is on targeted therapeutics to prevent healthy tissue
around the tumour zone from being damaged during treatment and
enable tumours to be accurately targeted. In its pursuit to
increase the drug uptake by cancerous cells, the company has
entered into an exclusive license agreement with the Centre
National de la Recherche Scientifique, the University Bordeaux I
and the Institut Polytechnique de Bordeaux, to get the development and
commercialisation rights over a biomimetic targeted strategy,
DriveIn® technology.
Clearly, ADOCIA continuously looks to stay on top of trends and
nurture its innovation capabilities. The company's solid
intellectual property portfolio, which comprises more than 150
patents and patent applications filed not only in France, but also in the United States only serves to reinforce its
strong innovative posture.
"Central to ADOCIA's success in the therapeutic proteins market
is its dual strategy, designed to penetrate both developing and
developed markets," noted Van
Cauwenberghe. "In developed countries, the company adopts a
value strategy, as these markets are driven by a strong demand for
first-in-class products. However, in emerging countries, the
company implements a volume strategy, as these markets are
characterised by a need for innovative products at affordable
prices."
Each year, Frost & Sullivan presents this award to the
company that has demonstrated uniqueness in developing and
leveraging new technologies, which significantly impact both the
functionality and the customer value of the new products and
applications. The award lauds the high R&D spend toward
innovation, its relevance to the industry and the positive impact
on brand perception.
Frost & Sullivan Best Practices awards recognise companies
in a variety of regional and global markets for demonstrating
outstanding achievement and superior performance in areas such as
leadership, technological innovation, customer service and
strategic product development. Industry analysts compare market
participants and measure performance through in-depth interviews,
analysis and extensive secondary research to identify best
practices in the industry.
About ADOCIA
To be a global leader in the innovative delivery of insulins
and therapeutic proteins
ADOCIA is a clinical-stage biotechnology company that
specializes in the development of innovative formulations of
already-approved therapeutic proteins. It has a particularly strong
expertise in the field of insulins. ADOCIA's proprietary
BioChaperone® technological platform is designed to enhance the
effectiveness and safety of therapeutic proteins and their ease of
use for patients.
ADOCIA has successfully completed two Phase I and IIa studies of
a fast-acting human insulin formulation (HinsBet®), one Phase I and
two Phase IIa studies of an ultra-fast-acting insulin lispro
(BioChaperone® Lispro U100) and a Phase I/II of a unique
combination of insulin glargine, the gold-standard of basal insulin
and insulin lispro, a fast-acting insulin analog (BioChaperone®
Combo).
A Phase IIa study of HinsBet® is ongoing and a dose-escalation
Phase IIa study of BioChaperone® Combo is scheduled for the fourth
quarter 2014. The company is also preparing a first clinical study
of a new ultra-fast concentrated insulin formulation based on
insulin lispro for 2015.
Ad ADOCIA ocia also completed one Phase I/II clinical study of
its product based on PDGF-BB for treating diabetic foot ulcer (BC
PDGF-BB). A Phase III clinical study was launched in India in August
2014.
ADOCIA has extended its activities to the formulation of
monoclonal antibodies, which are gold-standard biologics for the
treatment of various chronic pathologies (cancer, inflammation,
etc.). ADOCIA is engaged in collaborative programs with two major
pharmaceutical companies in this field.
Fighting cancer with targeted treatments
DriveIn® is a nanotechnology which is remarkably
efficient in delivering active compounds into cancer cells. This
new platform constitutes an exceptional opportunity to enter the
oncology market by improving the efficacy of both already approved
treatments and novel proprietary molecules.
"Innovative medicine for everyone, everywhere"
ADOCIA's therapeutic innovations aim to provide solutions in a
profoundly changing global pharmaceutical and economic context,
characterized by (i) an increased prevalence and impact of the
targeted pathologies, (ii) a growing and ageing population, (iii) a
need to control public health expenditures and (iv) an increasing
demand from emerging countries.
ADOCIA is listed on the regulated market of Euronext Paris
(ISIN: FR0011184241; Reuters/Bloomberg ticker: ADOC, ADOC.PA,
ADOC.FP) and is included in the Next Biotech index.
American Depositary Receipts representing ADOCIA common stock
are traded on the US OTC market under the ticker symbol ADOCY.
For more information, visit www.adocia.com
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in
collaboration with clients to leverage visionary innovation that
addresses the global challenges and related growth opportunities
that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these
opportunities and incorporating two key elements driving visionary
innovation: The Integrated Value Proposition and The Partnership
Infrastructure.
- The Integrated Value Proposition provides support
to our clients throughout all phases of their journey to visionary
innovation including: research, analysis, strategy, vision,
innovation and implementation.
- The Partnership Infrastructure is entirely unique
as it constructs the foundation upon which visionary innovation
becomes possible. This includes our 360 degree research,
comprehensive industry coverage, career best practices as well as
our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth
strategies for the global 1000, emerging businesses, the public
sector and the investment community. Is your organisation prepared
for the next profound wave of industry convergence, disruptive
technologies, increasing competitive intensity, Mega Trends,
breakthrough best practices, changing customer dynamics and
emerging economies?
Contact Us: Start the discussion
Join Us: Join our community
Subscribe: Newsletter on "the next big
thing"
Register: Gain access to visionary
innovation
Contact:
Gerard Soula
Chairman and CEO
ADOCIA
E: contactinvestisseurs@adocia.com
Tel.: +33-4-72-610-610
Caroline Carmagnol
ALIZE RP
E: caroline@alizerp.com
Tel.: +33-170-225-390
Kristina Menzefricke
Best Practices
Frost & Sullivan
E: kristina.menzefricke@frost.com
Tel.: +44-(0)20-7915-7869
